惠美仁簡介

HUIMEIREN Profile
BIOSTIME

        公司自成立以來,本著“以締造人類可持續健康為宗旨,以科技創新為動力”,憑借卓越的產品研發能力,經過多年的不斷自主創新、持續創新和加速發展,逐步成為國內BIO領域微生態健康行業的創新企業。

2015年4月29日,WHO(世界衛生組織)發布了一份題為《世界各地國家情況分析:應對抗微生物耐藥性》的新報告。這份全球首份耐藥性監控報告指出,抗生素耐藥性正嚴重威脅全球公共健康,基于對抗常見或嚴重疾病抗生素耐藥性的分析,諸多傳染病原正在產生耐藥性,這將直接導致病人患病時間更長,并增加其死亡風險。

中國是世界上濫用抗生素問題最嚴重的國家之一。統計資料顯示,平均而言,中國每人每年使用138克抗生素,是美國的10倍;約75%的季節性流感患者使用抗生素,住院患者抗生素處方率高達80%(世衛組織推薦的處方率為30%);約97%的手術患者被給予抗生素治療。

世界正在邁向“后抗生素時代”,面對抗生素耐藥性(AMR)問題日益嚴峻,嚴重威脅全球公共健康和國家安全,各國政府意識到目前應采取措施以阻止這場未來災難,而不知道應該“做什么”和“怎么做”的彷徨之際,沈陽惠美仁生物制品有限公司總經理兼惠美仁R&D中心研發團隊帶頭人崔泰興先生率先創新性地提出了以“抗生素為首的傳統‘殺菌消炎’治療的泛濫,益菌害菌通殺是違背自然規律的行為,引發了一場觸目驚心的人體醫療生態災難”;尖銳地指出了“抗生素耐藥性”是這場人體醫療生態災難的必然產物,該觀點與世界衛生組織(WHO)負責衛生安全和環境事務的助理總干事福田敬二博士觀點不謀而合。在此基礎上,崔泰興先生大膽提出了生態災難必須以生態方法解決的創新指導思想和研究方向;與時俱進地推出了解決其中婦科生態災難的切實可行的新型微生態生物制劑【善玉菌凍干活性因子】產品,成為了全行業備受矚目的焦點企業和備受社會認可和贊賞的責任企業。

現自主研發的【E菌婦自潔】婦科生殖系統系列、【E菌膚自潔】皮膚系統系列、【E血自潔】循環系統系列、【E肺自潔】呼吸系統系列、【E菌口自潔】、【E菌胃自潔】、【E菌腸自潔】及【E菌肛自潔】消化系統黏膜系列等全系統產品,在“抗生素耐藥性”的控制對策和治理“人體醫療生態災難”的公共健康方面,取得了突破性的進展。其中,部分產品已收到了良好的市場反應和效果,并以其廣闊的市場空間、核心技術優勢、行業壟斷地位及投資價值受到了眾多投資機構和海內外資本的青睞。

基于其對中國婦幼健康領域的杰出貢獻, 2012年“中華婦幼健康大會”授予公司總經理崔泰興先生為“全國婦幼健康行業十大領軍人物”榮譽稱號;公司拳頭產品【E菌婦自潔】也被確定為“中華婦幼健康大會重點推薦產品”;沈陽惠美仁生物制品有限公司也成為國內微生態健康領域的焦點企業和備受社會認可和贊賞的責任型企業。

Shenyang HuiMeiRen Biological Products Co., Ltd. is located in the Daoyi national economic and technological development Zone in Shenyang, Liaoning, China. HuiMeiRen is a high-tech enterprise, integrating R&D, manufacturing, and marketing of new probiotic products as a whole. Since its inception, HuiMeiRen has been aiming at creation of a sustainable health. Powered by scientific and technological innovations, HuiMeiRen has gradually become one of the relevant domestic industry leaders after years of continuous innovation and accelerated development.

The company’s Philosophy is that ecological disaster must be solved by ecological methods. Aiming at creation of a sustainable health, HuiMeiRen has been developing and manufacturing new types of the world advanced ecological products.

Facing the issue of antibiotic resistance, which is threatening the global stability and national security, people are urgently aware of the necessity of actions for prevention of this future disaster. However, there has been no clear idea about the actions, specially, in terms of “what to do” and “how to do” in this case. On this occasion of hesitation, Mr. Taixing Cui, the CEO and team leader of R&D center at HuiMeiRen, first pointed out innovatively that the traditional bactericidal anti-inflammatory therapy with antibiotics results in abuse of treatment by killing both beneficial and harmful bacteria simultaneously. Furthermore, it gives rise to a shocking ecological disaster in gynecology due to contrary to the laws of nature. Under this circumstance, Mr. Cui presented its innovative guiding ideology as a solution, which the ecological disaster must be solved by an ecological method. In the meanwhile, HuiMeiRen launched its series of probiotic products-【Shan Yu Jun Lyophilized Active Factor】as a practical solution of the disaster. Therefore, HuiMeiRen becomes a star enterprise, drawing broad industry-wide attentions.

Based on his outstanding contribution to the field of maternal and child health, Chinese Journal of Woman and Child Health Assembly in 2012 granted the honorary title “Top Ten national maternal and child health industry leaders” to Mr. Taixing Cui, the CEO of HuiMeiRen.

沈陽惠美仁生物制藥_益生菌廠家_企業介紹總經理:崔泰興
◎ 全國婦幼健康行業十大領軍人物
◎ 1984-1988. 就讀于遼寧大學生物學專業
◎ 1988-2000. 時任沈陽市生物化學制藥廠工程師
◎ 2001-2003. 時任日本國BMG株式會社制藥研究員,作為日本京都大學再生醫學研究所共同研究員參加多項日本國國家級科研項目,擔任細胞培養和動物實驗工作。